Who We Are

David was named President and CEO of Neuros in 2023, after serving as Chief Operating Officer since 2018.

Prior to Neuros, David worked for Cardiovascular Systems, Inc. (CSII), where he held a variety of senior executive positions and scaled the commercial organization from $50M in peripheral sales to over $250M in combined coronary and peripheral sales. During his tenure, David led the successful development of amputation prevention programs designed to drive awareness and access to care for underserved communities in the United States.

Prior to CSI, David served as General Manager for Stryker (SYK), where he led the creation of the Interventional Spine Division. David has also held key commercial leadership positions with Globus Medical (GMED) and other venture capital medical device companies.

David serves as a private equity advisor with Sectoral Asset Management. He earned a BS in Physiology from Chico State University and completed the Advanced Management Program at Harvard Business School.

Zach brings more than 20 years of finance, operations, and leadership experience to his new role at Neuros Medical.  Most recently, he served as Chief Financial Officer for ViewRay, Inc., a publicly traded company focused on cancer treatment.  Prior to ViewRay, he served as Chief Financial Officer and Chief Operating Officer for Bolder Surgical, an innovative, privately held surgical instrument company that was acquired by Hologic.  Prior to Bolder Surgical, he held various finance and business development roles at Spectranetics before its acquisition by Royal Philips. Zach holds a Master of Business Administration degree from the Kellogg School of Management at Northwestern University and a bachelor’s degree from Drake University.

Steve brings 20 years of medical device leadership experience building and leading successful commercial teams and launching disruptive products to his new role at Neuros Medical.  He was most recently the Vice President of Marketing and Medical Education for Apollo Endosurgery through the acquisition by Boston Scientific in 2023.  Prior to Apollo, he held various commercial leadership roles with small privately held and publicly traded companies including Torax Medical (acquired by Johnson & Johnson) and Synovis Life Technologies (acquired by Baxter).

Steve holds a Master of Business Administration degree from the Ross School of Business at the University of Michigan and a bachelor’s degree from Boston College.

Blair brings 25+ years of experience in the medical industry, heavily focused in the areas of vascular and cardiovascular disease states. He joins most recently from Endologix, where he served as the Eastern US Sales Manager.  Prior to Endologix, he served as Coronary Sales Director for Abbott Vascular.

Blair has launched numerous disruptive technologies, serving physicians and the patients that they treat in various leadership roles. He graduated from the University of Alabama with a bachelor’s degree in Public Relations and a minor in Marketing.

Michael has over 25 years of experience developing and commercializing medical technologies in both start-up and corporate environments. Prior to joining Neuros Medical, he served as Vice President of Product Development at StethX, Inc., an early-stage start-up. He also held the role of Director of Product Development for CardioMEMS at Abbott, where he was the first engineer and key technical expert behind the platform’s remote heart failure monitoring technology, leading its development from concept through commercialization.

Michael also serves as adjunct faculty at The Georgia Institute of Technology and Emory University’s Wallace H. Coulter Department of Biomedical Engineering. He holds ten issued patents and has successfully launched innovative products in cardiology and aortic aneurysm treatment throughout his career. He earned his Ph.D. in Electrical Engineering from The Georgia Institute of Technology in the field of wireless MEMS pressure sensors, which became foundational research for the CardioMEMS platform. Michael also received his M.S. and B.S. degrees in Electrical Engineering from The Georgia Institute of Technology.

Nick joined Neuros in 2022.

Prior to Neuros, Nick was at Cardiovascular Systems, Inc. (CSII), where he last served as the Director of Medical Affairs, responsible for scientific communication and patient safety. During his 8-year tenure, Nick was responsible for the creation of a Medical Science Liaison program and provided medical affairs expertise to support the acquisition, approval, and launch of new products.

Prior to industry, Nick had a 10+ year career in academic science with appointments at the National Institutes of Health, University of Virginia, and University of Minnesota.

Nick earned his PhD in Neuroscience from the University of Virginia, where he studied sodium channel function and gating alterations in epilepsy and chronic pain. His work resulted in numerous peer-reviewed publications funded through multiple individual NIH-supported grants. He received his BS in Neuroscience from Lafayette College.

Angelina’s career has been dedicated to the medical device industry for over 15+ years, with a strong focus on regulatory affairs, quality systems, and global compliance strategy. Prior to joining Neuros, she held leadership roles at Philips and Medtronic, where she supported new product development, global regulatory submissions, and EU MDR transitions across Class II and Class III portfolios. Her experience also includes regulatory work for drug-device combination products such as drug-coated balloons (DCBs) and stents, as well as software as a medical device (SaMD).

She has authored and led numerous U.S. FDA regulatory submissions, including Premarket Approval (PMA) applications, Traditional and Special 510(k)s, and Pre-Submissions. In addition to her U.S. experience, Angelina has supported a wide range of international regulatory submissions, including Technical Documentation for CE marking under the EU MDR, Health Canada license applications, and product registrations. She has worked closely with global regulatory bodies and Notified Bodies to ensure compliance with evolving requirements and has contributed to successful product launches across multiple regions.

Angelina’s expertise includes strategic regulatory engagement, global compliance planning, and audit readiness. Angelina holds a B.S. degree in Chemistry from Sonoma State University.

Melanie joined Neuros in 2018.

Prior to Neuros, she served as Vice President of Quality Assurance & Regulatory Compliance at Sequent Medical, Inc., acquired by Terumo Corporation in 2016 for up to $380M.

During her tenure, Melanie was instrumental in the development of the WEB Aneurysm Embolization System and in the procurement of both US PMA and international regulatory approvals.

Melanie is a subject-matter expert in medical device quality management systems and regulatory affairs. Throughout her 30-year career, she has driven outstanding results in audits (ISO, FDA/QSR) and approvals (CE, 510k, and PMA) in high-growth, new technology companies.

Melanie earned a BS from University of California-Irvine.